Showing results (11-20 of 48) with videos related to

Sort By:
Pageof 5
Bioconjugate Chemistry|October 12, 2011
90Y labeled phosphorodiamidate morpholino oligomer for pretargeting radiotherapyGuozheng Liu, Shuping Dou, Yuxia Liu, et al.
European Journal of Cancer (Oxford, England : 1990)|October 9, 2009
The ratio of maximum percent tumour accumulations of the pretargeting agent and the radiolabelled effector is independent of tumour sizeGuozheng Liu, Shuping Dou, Minmin Liang, et al.
European Journal of Nuclear Medicine and Molecular Imaging|September 1, 2005
Further investigations of morpholino pretargeting in mice--establishing quantitative relations in tumorGuozheng Liu, Jiang He, Shuping Dou, et al.
Molecular Pharmaceutics|May 29, 2010
Affinity enhancement pretargeting: synthesis and testing of a 99mTc-labeled bivalent MORFJiang He, Yi Wang, Shuping Dou, et al.
European Journal of Nuclear Medicine and Molecular Imaging|October 3, 2007
Pretargeting CWR22 prostate tumor in mice with MORF-B72.3 antibody and radiolabeled cMORFGuozheng Liu, Shuping Dou, P Hendrik Pretorius, et al.
Bioconjugate Chemistry|March 17, 2005
Affinity enhancement bivalent morpholino for pretargeting: initial evidence by surface plasmon resonanceJiang He, Guozheng Liu, Jean-Luc Vanderheyden, et al.
Bioconjugate Chemistry|November 18, 2004
Preparation and properties of 99mTc(CO)3+-labeled N,N-bis(2-pyridylmethyl)-4-aminobutyric acidGuozheng Liu, Shuping Dou, Jiang He, et al.
Frontiers in Pharmacology|August 9, 2014
Differentiation between temporary and real non-clearability of biotinylated IgG antibody by avidin in miceShuping Dou, John Virostko, Mary Rusckowski, et al.
Cancer Letters|August 30, 2008
A new TAG-72 cancer marker peptide identified by phage displayLing Chen, Yi Wang, Xinrong Liu, et al.
Cancer Biotherapy & Radiopharmaceuticals|January 6, 2011
Adding a clearing agent to pretargeting does not lower the tumor accumulation of the effector as predictedGuozheng Liu, Shuping Dou, Xiangji Chen, et al.
Pageof 5